Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that a recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of […]
continue readingCardior Pharmaceuticals‘ Lead Compound Demonstrates Improvement of Heart Function in Chronic Heart Failure Model
Safety and efficacy of CDR132L established in an in vivo model of chronic post-MI heart failure Study by international research team published in European Heart Journal Broad treatment potential for chronic heart failure Cardior Pharmaceuticals GmbH, a clinical-stage biotech company, focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today […]
continue readingCardior Pharmaceuticals Demonstrates Reversal of Cardiac Hypertrophy by H19 Gene Therapy
Administration of AAV9 expressing H19 attenuates cardiac hypertrophy in vivo and prevents progression to heart failure Details on novel mechanism of action published in peer-reviewed study in the European Heart Journal Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced the […]
continue reading